IPM Take
Cancer systems love escalation. ENDURANCE is important because it asks the opposite question: when is enough enough? If stopping lenalidomide after two years can preserve survival for selected standard-risk patients, then de-escalation becomes an access policy, a toxicity policy and a financial policy.
Executive Summary
Results from the Phase III ENDURANCE trial, published in The New England Journal of Medicine and reported by ASCO Post on 15 July, showed no overall survival benefit from indefinite lenalidomide maintenance compared with stopping after two years in standard-risk newly diagnosed multiple myeloma patients who did not undergo autologous stem-cell transplant. With a median follow-up of seven years, overall survival was 69.0% with indefinite lenalidomide and 68.6% with limited-duration therapy. Median progression-free survival was 42.5 months versus 38.9 months. Grade 3–5 treatment-related non-haematologic toxicity was higher with indefinite treatment, at 23.5% versus 16.9%.
Why it matters
- Patients / advocates: Maintenance therapy becomes part of daily life. A fixed duration could reduce treatment burden without sacrificing survival in selected patients.
- Clinicians: The trial gives evidence for shared decision-making in standard-risk, non-transplant myeloma.
- Payers: The cost implications are major, particularly as myeloma survival improves and maintenance duration expands.
- Researchers / academia: Cooperative-group trials remain essential for answering questions industry has little incentive to prioritise.
Not every important cancer trial introduces a new drug.
Some of the most important trials ask whether patients can safely receive less.
ENDURANCE is one of those trials. In newly diagnosed, standard-risk multiple myeloma patients who did not undergo transplant, continuing lenalidomide maintenance until progression did not improve overall survival compared with stopping after two years. Seven-year overall survival was essentially identical: 69.0% versus 68.6%.
That finding matters because maintenance therapy is not abstract. It is tablets, blood tests, clinic visits, adverse events, anxiety, cost and the psychological weight of never being done.
The progression-free survival difference was modest: 42.5 months with indefinite treatment versus 38.9 months with limited-duration therapy. But toxicity moved in the other direction. Grade 3–5 treatment-related non-haematologic toxicity was 23.5% with indefinite maintenance and 16.9% with the two-year approach. Second primary cancers were also numerically higher with indefinite therapy, at 11.2% versus 8.3%.
This is where de-escalation becomes political.
Cancer systems are structurally better at paying for more than at deciding when less is enough. Guidelines, reimbursement models and clinical habits often drift toward continuation because stopping feels risky. But indefinite treatment also has consequences. It can make toxicity normal. It can make cost invisible. It can make patients carry therapy long after the benefit becomes uncertain.
ENDURANCE does not say every myeloma patient should stop maintenance at two years. The population matters: standard-risk patients, no transplant, biomarker-defined exclusions for high-risk features. But it does say that duration deserves evidence, not habit.
This is the kind of trial health systems should want more of: not because it sells innovation, but because it makes care more honest
